Pharmaceutical Tariffs Raise Concerns for Innovation Economy and Emerging Biotech
The White House this past week announced a sweeping new tariff policy targeting imported patented pharmaceutical products, positioning the move as a national security measure to strengthen U.S. supply chains and incentivize domestic manufacturing.
While the goal of bolstering U.S.-based biomanufacturing aligns with long-standing industry priorities, the structure and scope of the policy are raising significant concerns across the biotechnology sector - particularly for small and mid-sized innovators that drive much of the nation’s therapeutic pipeline.
What the Policy Proposes
The Administration’s plan would impose tariffs - reportedly up to 100% - on certain branded (patented) medicines imported into the United States. Companies may mitigate tariff exposure by agreeing to “most favored nation” (MFN) pricing structures or committing to U.S.-based manufacturing investments.
The policy is intended to:
-
Reduce drug prices domestically
-
Encourage reshoring of pharmaceutical manufacturing
-
Strengthen national security by reducing reliance on foreign supply chains
However, industry stakeholders caution that tariffs on medicines may have unintended - and counterproductive - effects.
Innovation at Risk: Industry Perspective
National biotechnology leaders, including the Biotechnology Innovation Organization (BIO), have raised strong concerns about the policy’s potential impact.
BIO President & CEO John Crowley emphasized that while strengthening domestic manufacturing is a shared goal, tariffs on medicines risk undermining the very ecosystem they aim to protect - by raising costs, delaying development, and diverting resources away from innovation.
Critically, BIO notes that:
-
Small and mid-sized biotech companies develop more than half of FDA-approved medicines
-
These companies typically lack the capital to rapidly build or relocate manufacturing infrastructure
-
Tariffs and pricing mandates may reduce already constrained R&D investment
The concern is not theoretical - early analysis and reporting suggest that the burden of compliance and cost increases will fall disproportionately on emerging biotech companies.
Why Smaller Biotech Companies Are Disproportionately Affected
While large pharmaceutical firms may have the scale and capital to adapt - through domestic manufacturing investments or negotiated pricing agreements - smaller biotech companies face structural disadvantages:
Limited Manufacturing Flexibility
Early-stage and mid-sized biotech firms rely heavily on global contract manufacturing networks. Building U.S.-based capacity is capital-intensive and often not feasible during clinical development stages.
Capital Constraints in a High-Risk Industry
Biotech innovation is already defined by long timelines, high failure rates, and significant upfront investment. Tariffs introduce additional cost pressures at the exact stage when companies are most financially vulnerable.
Diversion of Resources from R&D
As BIO highlights, tariffs risk redirecting scarce capital away from research and clinical development - potentially delaying or halting new therapies.
Policy Design That Favors Scale
Coverage from InsideHealthPolicy and others suggests the policy may create a two-tier system, where large companies can absorb costs or qualify for exemptions, while smaller innovators face disproportionate barriers.
MichBio Perspective: Aligning Security Goals with Innovation Reality
MichBio supports efforts to strengthen U.S. biomanufacturing and reduce vulnerabilities in critical supply chains - goals that align with Michigan’s leadership in advanced manufacturing and life sciences.
At the same time, this policy highlights a fundamental challenge:
Ensuring that efforts to enhance national security do not inadvertently weaken the innovation ecosystem that produces new cures and drives economic growth.
Michigan’s life sciences sector depends on a balanced ecosystem that includes startups, emerging biotech companies, and global manufacturers. Policies that increase costs or uncertainty for early-stage innovators risk slowing the development of next-generation therapies and weakening U.S. competitiveness globally.
As BIO underscores, tariffs - particularly when combined with MFN pricing pressures - may ultimately:
-
Undermine domestic investment rather than encourage it
-
Reduce U.S. competitiveness relative to global biotech hubs, including China
-
Delay patient access to innovative treatments
MichBio stands with BIO and industry partners in calling for a more effective, long-term strategy to strengthen U.S. biopharmaceutical leadership, including:
-
Incentives to expand domestic biomanufacturing capacity
-
Policies that reduce the time, cost, and uncertainty of drug development
-
Support for emerging biotech companies that drive innovation
-
International frameworks that ensure American innovation is fairly valued
As implementation details continue to emerge, it will be critical for policymakers to engage with stakeholders across the full life sciences ecosystem.
The shared objective is clear: a resilient, secure, and globally competitive U.S. biotechnology sector. Achieving that goal will require policies that enable innovation - not constrain it.
